Roche
As of the edition of 20 October 2026, Roche runs 419 drugs, 114 of them marketed; it is on route A at 86 targets and on route B at 37 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 15 company names in this family.
- F. Hoffmann-La Roche AG: acquired in 2009; successor Hoffmann-La Roche
- Memory Pharmaceuticals: acquired
Drugs by status
| Status | Count |
|---|---|
| Marketed | 114 |
| Active | 88 |
| Went quiet | 114 |
| Stopped | 70 |
| Withdrawn from market | 3 |
| Status not established | 30 |
| Total | 419 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Bevacizumab | Ends 2027 (orphan exclusivity) | 2 |
| Rituximab | Ends 2028 (orphan exclusivity) | 1 |
| Fluorouracil | none listed | 2 |
| Capecitabine | none listed | 1 |
| Trastuzumab | Ended 2017 (orphan exclusivity) | 0 |
| Atezolizumab | Ends 2029 (orphan exclusivity) | 1 |
| Midazolam | none listed | 1 |
| Erlotinib | none listed | 2 |
| Ribavirin | none listed | 1 |
| Mycophenolate mofetil | none listed | 1 |
| Tocilizumab | Ends 2028 (orphan exclusivity) | 0 |
| Peginterferon alfa-2a | Ended 2014 (computed from the first US licence) | 0 |
| Ranibizumab | Ended 2018 (computed from the first US licence) | 0 |
| Obinutuzumab | Ended 2025 (computed from the first US licence) | 0 |
| Somatropin | Ended 2003 (orphan exclusivity) | 4 |
| Pertuzumab | Ended 2024 (reference-product exclusivity) | 0 |
| Ketorolac | none listed | 6 |
| Levodopa | none listed | 4 |
| Tretinoin | none listed | 3 |
| Omalizumab | Ended 2015 (computed from the first US licence) | 1 |
| Isoniazid | none listed | 0 |
| Vemurafenib | Ends 2030 (patent) | 1 |
| Alteplase | Ended 1999 (computed from the first US licence) | 0 |
| Isotretinoin | none listed | 3 |
| Trastuzumab emtansine | Ended 2025 (computed from the first US licence) | 0 |
A route B row is one company at one target. 89 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 86 targets, route B at 37 targets.
All 123 rows on route A or B
In the product123 company-target rows on route A or B; 120 are not shown here, and no score is.
See all 123 targets where Roche needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 579 trials led
- Immune system: 286 trials led
- Skin and connective tissue: 241 trials led